These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17181934)

  • 21. Evaluation of the benefits of sequential addition of leflunomide in patients with polyarticular course juvenile idiopathic arthritis failing standard dose methotrexate.
    Chickermane PR; Khubchandani RP
    Clin Exp Rheumatol; 2015; 33(2):287-92. PubMed ID: 25738527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM
    Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study.
    van der Meer A; Wulffraat NM; Prakken BJ; Gijsbers B; Rademaker CM; Sinnema G
    Clin Exp Rheumatol; 2007; 25(3):480-5. PubMed ID: 17631750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining cyclosporine with prevailing antirheumatic drug therapy in the treatment of juvenile idiopathic arthritis.
    Haapasaari J; Kautiainen H; Hakala M
    Clin Exp Rheumatol; 2002; 20(2):259. PubMed ID: 12051414
    [No Abstract]   [Full Text] [Related]  

  • 25. Impact of the European paediatric legislation in paediatric rheumatology: past, present and future.
    Ruperto N; Vesely R; Saint-Raymond A; Martini A;
    Ann Rheum Dis; 2013 Dec; 72(12):1893-6. PubMed ID: 23962457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis.
    Céspedes-Cruz A; Gutiérrez-Suárez R; Pistorio A; Ravelli A; Loy A; Murray KJ; Gerloni V; Wulffraat N; Oliveira S; Walsh J; Penades IC; Alpigiani MG; Lahdenne P; Saad-Magalhães C; Cortis E; Lepore L; Kimura Y; Wouters C; Martini A; Ruperto N;
    Ann Rheum Dis; 2008 Mar; 67(3):309-14. PubMed ID: 17875547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis.
    Nerome Y; Imanaka H; Nonaka Y; Takei S
    Mod Rheumatol; 2007; 17(6):526-8. PubMed ID: 18084710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Network in pediatric rheumatology: the example of pediatric rheumatology international trials organisation.
    Ruperto N; Martini A
    Georgian Med News; 2008 Mar; (156):68-74. PubMed ID: 18403813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study.
    Quartier P; Alexeeva E; Constantin T; Chasnyk V; Wulffraat N; Palmblad K; Wouters C; I Brunner H; Marzan K; Schneider R; Horneff G; Martini A; Anton J; Wei X; Slade A; Ruperto N; Abrams K;
    Arthritis Rheumatol; 2021 Feb; 73(2):336-346. PubMed ID: 32783351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
    Tynjälä P; Vähäsalo P; Tarkiainen M; Kröger L; Aalto K; Malin M; Putto-Laurila A; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2011 Sep; 70(9):1605-12. PubMed ID: 21623000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.
    Bakker MF; Jacobs JW; Welsing PM; Verstappen SM; Tekstra J; Ton E; Geurts MA; van der Werf JH; van Albada-Kuipers GA; Jahangier-de Veen ZN; van der Veen MJ; Verhoef CM; Lafeber FP; Bijlsma JW;
    Ann Intern Med; 2012 Mar; 156(5):329-39. PubMed ID: 22393128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.
    Vastert SJ; de Jager W; Noordman BJ; Holzinger D; Kuis W; Prakken BJ; Wulffraat NM
    Arthritis Rheumatol; 2014 Apr; 66(4):1034-43. PubMed ID: 24757154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.
    Chang CY; Meyer RM; Reiff AO
    Arthritis Care Res (Hoboken); 2015 May; 67(5):658-66. PubMed ID: 25220674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
    Aikawa NE; França IL; Ribeiro AC; Sallum AM; Bonfa E; Silva CA
    Vaccine; 2015 Jan; 33(5):604-9. PubMed ID: 25554240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
    Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
    Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients.
    Romano M; Pontikaki I; Gattinara M; Ardoino I; Donati C; Boracchi P; Meroni PL; Gerloni V
    Reumatismo; 2014 Mar; 65(6):278-85. PubMed ID: 24705031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
    Rider LG; Aggarwal R; Pistorio A; Bayat N; Erman B; Feldman BM; Huber AM; Cimaz R; Cuttica RJ; de Oliveira SK; Lindsley CB; Pilkington CA; Punaro M; Ravelli A; Reed AM; Rouster-Stevens K; van Royen-Kerkhof A; Dressler F; Magalhaes CS; Constantin T; Davidson JE; Magnusson B; Russo R; Villa L; Rinaldi M; Rockette H; Lachenbruch PA; Miller FW; Vencovsky J; Ruperto N;
    Arthritis Rheumatol; 2017 May; 69(5):911-923. PubMed ID: 28382778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis.
    Papadopoulou C; Kostik M; Böhm M; Nieto-Gonzalez JC; Gonzalez-Fernandez MI; Pistorio A; Martini A; Ravelli A
    J Pediatr; 2013 Sep; 163(3):879-84. PubMed ID: 23664559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of long-term remission of oligo/polyarticular juvenile idiopathic arthritis with S100A12 and vascular endothelial growth factor.
    Yamasaki Y; Takei S; Imanaka H; Nerome Y; Kubota T; Nonaka Y; Akaike H; Takezaki T; Kawano Y
    Mod Rheumatol; 2016 Jul; 26(4):551-6. PubMed ID: 26474088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.